WO1990007952A1 - Treatment methods and vaccines - Google Patents
Treatment methods and vaccines Download PDFInfo
- Publication number
- WO1990007952A1 WO1990007952A1 PCT/US1990/000275 US9000275W WO9007952A1 WO 1990007952 A1 WO1990007952 A1 WO 1990007952A1 US 9000275 W US9000275 W US 9000275W WO 9007952 A1 WO9007952 A1 WO 9007952A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- patient
- blood
- cell
- methoxypsoralen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
Definitions
- the present invention relates to t h e f iel d o f immunology, particularly methods for inactivating and/or attenuating viruses and/or virus infecte d cells, particularly virus infected CD 4 cells, using photopheresis and employing said inactivated and/or attenuated viruses and/or virus infected cells to engender an immune response.
- a particular aspect of the invention relates to the treatment of patients who are infected with a virus, particularly an HI V retrovirus, and who have an abnormally l ow white b loo d cell count, by using photopheresis in com b ination with the administration of a photoactive compound such as 8 -methoxypsoralen.
- a photoactive compound such as 8 -methoxypsoralen.
- Compoun d s for use in the manufacture of medicaments for the therapeutic treatment of such virus infections are also described.
- the invention also relates to vaccines against viruses, particularly HIV retroviruses , and methods for producing sai d vaccines.
- Retroviruses form a sub-group of RNA viruses which, in order to replicate, must first employ reverse transcription of the RNA of their genome into DNA ("transcription" conventionally describes the synthesis of RNA from DNA) .
- the viral genome is incorporated into the host cell genome, allowing it to take full advantage of the host cell's transcription/translation machinery for the purpose of replication. Once incorporated into the host cell's DNA, the virus may persist for as long as the cell lives.
- retroviruses are known to cause a depression in an infected patient's white blood cell count. This sub-set of retroviruses which reduce white blood cell count are known as Human Immunodeficiency Viruses (HIV) .
- HIV Human Immunodeficiency Viruses
- HIV retroviruses have been isolated from patients who suffer from Acquired Immune Deficiency Syndrome (AIDS) and have been given the designations HIV 1 and HIV 2, sometimes collectively referred to as "HTLV III", “LAV” or simply "HIV". These retroviruses will infect cells expressing the CD4 marker, such as human T- lymphocytes and monocytes. These cells are involved in the functioning of the immune system. This infection, in turn, results in the progressive loss of the CD4 T-cell population and disturbs the function of other CD 4 cells, such as monocytes, thereby reducing the patient's ability to combat other infections, and predisposing the patient to opportunistic infections which frequently prove fatal .
- CD4 marker such as human T- lymphocytes and monocytes.
- AIDS infection There are at least three clinical manifestations of AIDS infection.
- the only indication of infection is either the presence of HIV antibodies in the blood ⁇ stream or the ability to culture the virus.
- the next stage is known as 'AIDS related complex' (ARC) and the physical symptoms associated therewith may include persistent general lymphadenopathy, general malaise, increased temperature and chronic infections. This condition usually progresses to the final, fatal AIDS condition, when the patient loses the ability to fight infection.
- RNA to DNA reverse transcription process is fraught with repeated mutation which makes it extremely . difficult for the body's immune system to recognize and attack infected cells along with the virus itself.
- an object of this invention to provide a method of treating virus infections in patients having an abnormally low white blood cell count. It is a further object of the invention to provide a method of treating patients infected with an HIV retrovirus.
- a still further object of the invention is to provide a vaccine against virus infections, particularly when the infection is caused by a retrovirus such as an HIV retrovirus.
- a method for treating patients who are infected with a virus, particularly an HIV retrovirus, using a photoactive compound that binds, in the case of a virus infected cell, to the cell membrane (e.g., by binding to a receptor and/or a nucleic acid fragment on the cell membrane) and/or to nucleic acid in the cell nucleus or cell cytoplasm, or, in the case of either free virus or cell associated virus, that binds to the virus surface (e.g., to a receptor and/or to a nucleic acid fragment on the virus surface) and/or to nucleic acid (e.g., DNA or RNA) which is incorporated in the virus, upon activation by exposure to electromagnetic radiation of a prescribed spectrum, such as ultraviolet light, for the purpose of inactivating and/or attenuating the virus and permitting the so treated virus and/or virus
- an especially important feature of the present invention is that the treatment methods described herein are used in patients having an abnormally low number of circulating lymphocytes or white blood cells.
- the treatment methods according to the invention can be used to reconstitute the immune system's function in such patients. This is of tremendous importance in the treatment of ARC/AIDS patients who, in addition to having an HIV infection (which itself has heretofore been extremely difficult to treat) , also have a depressed immune system. Such patients generally cannot tolerate a reduction in the number of their lymphocytes or white blood cells without succumbing to opportunistic infections.
- the treatment methods in accordance with the present invention are useful to control HIV and other retrovirus infections in patients having an abnormally low white blood cell level, without causing a harmful depression of the patient's immune system. Accordingly, the methods of the invention can be employed in the treatment of conditions such as ARC/AIDS without subjecting the treated patient to a risk of opportunistic infection.
- the treatment methods in accordance with the invention may also be used in such patients to improve the functioning of their immune systems.
- HIV retroviruses may also be responsible for causing diseases other than AIDS. The inventors believe that the inventive methods should be useful for treating such other diseases as well.
- a photoactive compound such as 8-methoxypsoralen is administered to the patient's blood, or some fraction thereof, in vitro or in vivo using conventional administration routes.
- a portion of the patient's blood is then treated (preferably, extracorporeally) using photopheresis, which comprises subjecting the blood to electromagnetic radiation in a wavelength suitable for activating the photoactive compound, such as ultraviolet light, preferably long wavelength ultraviolet light in the wavelength range of 320 to 400 nm, commonly called UVA light.
- the treated blood, or a fraction thereof is returned to the patient (in the case of extracorporeal photopheresis) or remains in the patient (following in vivo photopheresis) .
- Vaccines against viruses and methods of making same are also provided according to the invention.
- a photoactive compound as described herein is administered to the blood or some fraction thereof of a donor who is infected with a virus, such as an HIV retrovirus and/or who is suffering from AIDS or AIDS Related
- At least a portion of the donor's blood is then treated using photopheresis, as described above.
- the treated blood or some fraction thereof eg. , treated free isolated virus
- treated virus infected cells along with the treated virus in order to obtain the desired immune response.
- the treated blood is processed by conventional techniques to substantially remove the erythrocytes.
- the resulting processed fraction is then used as a vaccine which can be administered to a patient.
- the invention also concerns medicaments for the therapeutic treatment of virus infections in patients having an abnormally low white blood cell count and for the therapeutic treatment of HIV infections, particullarly an HIV 1 infection or an HIV 2 infection, as well as for the therapeutic treatment of a patient who is an AIDS Carrier or who has AIDS or AIDS Related Complex.
- Fig. 1 is a block diagram of a photopheresis apparatus which can be used to practice the inventive methods;
- Fig.2 is a graph of changes in CD 4 cells and
- Fig. 3 is a graph of changes in GP24 antibody levels of the five patients treated in Example 2
- Fig. 4 is a graph of changes in GP120 antibody levels of the five patients treated in Example 2;
- Fig. 5 is a graph of changes in CD 4 helper cell percentages of the five patients treated in Example 2.
- the photopheresis treatment method according to the invention is of particular value in the treatment of frequently mutating viral infections, such as retroviruses, for instance HIV retroviruses.
- treated infected cells as well as killed and/or attenuated virus, peptides, native sub-units of the virus itself (which are released upon cell break-up and/or shed into the blood) and/or pathogenic noninfectious viruses may be used.
- the treatment methods according to the invention provide a dynamic autogenous vaccine against viral infections.
- inventive methods have been found by the inventors to be useful in the treatment of patients having a virus infection and who have an abnormally low white blood cell count and are particullarly useful in treating HIV retrovirus infections.
- inventive methods are also particullarly useful for treating patients who are AIDS Carriers or who have AIDS or AIDS Related Complex.
- a photoactive compound is first administered to the blood of a patient who is infected with a virus.
- the photoactive compound may be administered in vivo (e.g. orally or intravenously) or may be administered in vitro to a portion of the patient's blood which has been removed from the patient by employing conventional blood withdrawal techniques.
- free virus is isolated from infected cells using conventional virus isolation methods which are known in the art.
- the photoactive compound can be administered to the infected cells prior to virus isolation or can be administered to the free isolated virus. In the case of treating HIV infection, however, it is presently preferred to use both treated virus and treated virus infected cells in the methods described hereinbelow.
- the photoactive compound selected should preferably be one that binds, in the case of a virus infected cell, to the cell membrane (e.g., by binding to a receptor and/or a nucleic acid fragment on the cell membrane) and/or to nucleic acid in the cell nucleus or cell cytoplasm, or, in the case of either free virus or cell associated virus, that binds to the virus surface (e.g., to a receptor and/or to a nucleic acid fragment on the virus surface) and/or to nucleic acid (e.g., DNA or RNA) which is incorporated in the virus, upon activation by exposure to electromagnetic radiation of a prescribed spectrum, such as ultraviolet light, for the purpose of inactivating and/or attenuating the virus and permitting the so treated virus and/or virus infected cells to be presented to the immune system of the patient.
- Psoralen compounds are particularly preferred for this purpose, especially the compound 8- methoxypsoralen — in which case UVA radiation is preferred
- the portion of the patient's blood, or the free isolated virus, to which the photoactive compound has been administered is treated by subjecting the portion of the blood, or the free isolated virus, to photopheresis using said electromagnetic radiation — for example, ultraviolet light.
- the photopheresis step is preferably carried out in vitro using an extracorporeal photopheresis apparatus.
- the photopheresis step in accordance with the present invention may also be carried out in vivo.
- a presently preferred extracorporeal photopheresis apparatus for use in the methods according to the invention is currently manufactured by Therakos, Inc., Westchester, Pennsylvania under the name TJVAR.
- TJVAR Therakos UVAR photopheresis apparatus
- a description of the Therakos UVAR photopheresis apparatus may be found in U.S. Patent No. 4,683,889, granted to R.L. Edelson on August 14, 1987, the contents of which are hereby incorporated by reference in their entirety.
- the apparatus includes a pump 10 for removing blood from the patient via a donor needle placed in an appropriate vein of the patient; an irradiation chamber 20; a radiation source 30 in close proximity to the irradiation chamber and a centrifuge 40, preferably of the continuous type.
- the various parts of the apparatus such as tubing collection bags for the blood and the like, which come in contact with -li ⁇
- the patient's blood or some fraction thereof are preferably replaceable so that they may be disposed of after each use to prevent the possibility of transmitting blood-borne infections from one patient to others who are subsequently treated with the apparatus.
- the photopheresis step is carried out in vitro, at least a fraction of the treated blood, or the treated free isolated virus, is returned to the patient following the photopheresis treatment.
- the treatment method described hereinabove is repeated at an interval of about once per week to about once every four weeks.
- the treatment methods described herein are administered on two successive days and repeated approximately once per month (ie, the patient preferably receives two treatments every month) .
- the treatment parameters ie, dosage of the photoactive compound and electromagnetic radiation, periodicity of treatment (e.g., monthly, weekly, etc.) and the number of treatments administered in each period ( e.g., twice per month on two successive days) —depending on the condition of the patient and the patient's response to the treatment.
- Preferred photoactive compounds for use in accordance with the present invention are compounds known as psoralens (or furocoumarins) which are described in U.S. Patent No. 4,321,919 the disclosure of which is incorporated herein by reference in their entirety.
- the preferred photoactive compounds for use in accordance with the present invention include the following: psoralen;
- the most particularly preferred photoactive compound for use in accordance with the invention is 8-methoxypsoralen.
- the photoactive compound when administered to the patient's blood in vivo is preferably administered orally, but also can be administered intravenously and/or by other conventional administration routes.
- the preferred dosage of the photoactive compound is in the range of about 0.3 to about 0.7 mg/kg of body weight although larger or smaller doses may be employed.
- the photoactive compound When administered in vitro to only a portion of the patient's blood or fraction thereof, it is within the ability of those skilled in the art to calculate a dosage which is equivalent to said range based upon the volume of treated blood or fraction thereof.
- the photoactive compound When administered orally, should preferably be administered at least about one hour prior to the photopheresis treatment and no more than about three hours prior to the photopheresis treatment. The timing of administration may be adjusted up or down as needed depending on the bioavailability of the photoactive compound, its expected half-life, etc. If administered intravenously, the times would generally be shorter.
- the photopheresis treatment in the treatment methods according to the invention is preferably carried out using long wavelength ultraviolet light (UVA) at a wavelength within the range of 320 to 400 nm.
- UVA long wavelength ultraviolet light
- the exposure to ultraviolet light during the photopheresis treatment preferably has a duration of about three to four hours, although shorter or longer treatment periods may be used if desired.
- the exposure of virus infected cells and/or virus thereto, following administration of the photoactive compound should be of sufficient intensity/duration to effectively inactivate and/or attenuate the virus.
- the selection of an appropriate wavelength for photopheresis as well as the exposure, depending upon the photoactive compound being employed and the conditions of treatment is within the ability of those skilled in the art in view of the present disclosure.
- the photoactive compound is 8- methoxypsoralen
- an exposure to UVA radiation of about 2 Joules/meter ⁇ based upon the surface area of the virus and virus infected cells undergoing treatment.
- the invention provides a novel treatment for patients who are infected by a virus and who have depressed immune systems as a result of such infection, as well as for patients who are infected with an HIV retrovirus or who are AIDS
- the treatment methods according to the invention have been found by the inventors to be safe in this latter regard while also being effective in combatting HIV infection in humans.
- the . invention also provides methods for making vaccines.
- a donor who is infected with a virus, such as an HIV retrovirus may be utilized to produce a vaccine against his infection as follows.
- a photoactive compound as described hereinabove is administered to at least a portion of the donor's blood containing free virus and/or virus infected cells either prior to removal of the blood, either orally or intravenously, or after removal from the donor in which case it is administered in vitro.
- a portion of the donor's blood could first be processed using known methods to substantially remove the erythrocytes and the photoactive compound is then administered to the resulting fraction.
- the portion of blood (eg. , an enriched leukocyte fraction thereof) and/or free isolated virus to which the photoactive compound has been administered is subjected to a photopheresis treatment using electromagnetic radiation of a prescribed spectrum, e.g. ,ultraviolet light, preferably UVA, in the manner previously described.
- a photopheresis treatment using electromagnetic radiation of a prescribed spectrum, e.g. ,ultraviolet light, preferably UVA, in the manner previously described.
- the treated blood, the treated portion thereof or the treated free isolated virus (as the case may be) is then administered back to the donor as an autogenous vaccine.
- the treated virus can also be isolated from the treated blood or portion thereof following photopheresis treatment for use as a vaccine.
- the treated blood which is itself a mixture of various blood components including peptides or polypeptides, eg., cytokines, lymphokines, monokines, etc., and/or the treated, portion of blood may be processed, as is within the ability of persons having ordinary skill in the art, to isolate a particular component or components which may be used in the treatment of the virus infection of the donor and/or may be used as a vaccine against the virus.
- peptides or polypeptides eg., cytokines, lymphokines, monokines, etc.
- EXAMPLE 1 A male patient, 39 years of age, weighing approximately 70 kg and who had been diagnosed as having AIDS Related Complex was treated in accordance with the present invention as follows:
- 8-methoxypsoralen was administered orally to the patient during the afternoon of the first day of treatment at a dosage of 30 mg (i.e. about 0.4 mg/kg) .
- a centrifuge which is integral with the photopheresis machine was used to spin off substantially all of the erythrocytes from the withdrawn blood and these were subsequently returned to the patient.
- the blood parameters of the patient before receiving the photopheresis treatment according to the invention and five weeks after receiving the treatment are set forth in Table 1.
- the patient who had a negative mumps skin test (which was carried out in the usual manner known in the art) prior to receiving the treatment in accordance with the present invention as described hereinabove, developed a positive mumps skin test after six monthly treatments in accordance with the present invention— this positive mumps skin test being documented by skin biopsy demonstrating the characteristic histologic changes of delayed hypersensitivity.
- This patient continued to receive the described treatment on two successive days on a monthly basis as part of a clinical study involving five patients, the results of which are discussed in Example 2 below in which this patient is identified as patient No. 1.
- the first patient treated (the patient in Example 1, above) , a homosexual male who before treatment was able to walk up a flight of stairs only with difficulty, is now capable of jogging three and one-half miles per day and of lifting weights.
- the one patient who did not seem to have a persistent rise in energy level was the female reformed intravenous drug abuser with three small children. Although her fatigue had been chronic prior to her entry into the study, no persistent change in energy level was observed after therapy. Additional clinical observations include increased appetite and weight stability in four of the patients, the exception being the female who lost 3.3 kg over the six month treatment period. Ly phadenopathy disappeared in all five patients by the third month and has remained absent. The four male patients also regained delayed cutaneous hypersensitivity after six months of therapy. During the six-month period of treatment all patients were able to manage common community-acquired upper respiratory tract infections without difficulty.
- hemoglobin and hematocrit, reticulocyte count, and platelet count remained stable.
- white blood count There were minor variations in the white blood count, and circulating total lymphocytes remained stable in the four male patients; however, the single female patient showed a decrease in white blood count (4,000 prior to treatment to 2,000 after six months of therapy) and a parallel decrease in lymphocytes.
- ESR, urinalysis, and SMAC-20 remained unchanged with the exception of minor rises in serum SGOT and SGPT.
- EBV titers remained constant in all but one patient in whom the IgG capsid antigen decreased from a titer of 1:1280 to a titer of 1:160 paralleling an increse in HIV antibody titers.
- CMV titers remained unchanged in all patients. Those patients who were P24 antigen negative remained negative; those who were positive remained positive, and no changes in titer occured by the end of the six-month period. Viral cultures of blood for HIV turned negative in one patient (Patient No. 3) but remained positive in the others after the reported therapy.
- the photoactive compounds described herein may be formulated using standard techniques which are already known in the art and, therefore, shall not be described in detail herein.
- the photoactive compounds may be formulated using conventional excipients in the form of tablets, capsules and the like which would be suitable for oral administration.
- the photoactive compounds described herein may, if desired, be formulated for parenteral administration by intravenous or intramuscullar routes.
- the medicaments can also be formulated as injectable solutions or suspensions for in vitro administration to a blood fraction which has been removed from an infected donor.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI913318A FI105453B (en) | 1989-01-10 | 1991-07-09 | A method of producing a vaccine against HIV retroviral infection |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/295,454 US4960408A (en) | 1989-01-10 | 1989-01-10 | Treatment methods and vaccines for stimulating an immunological response against retroviruses |
US295,454 | 1989-01-10 | ||
US36406389A | 1989-06-08 | 1989-06-08 | |
US364,063 | 1989-06-08 | ||
US46081190A | 1990-01-04 | 1990-01-04 | |
US460,811 | 1990-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990007952A1 true WO1990007952A1 (en) | 1990-07-26 |
Family
ID=27404363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/000275 WO1990007952A1 (en) | 1989-01-10 | 1990-01-10 | Treatment methods and vaccines |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0453497A4 (en) |
JP (1) | JPH04502621A (en) |
AU (1) | AU638693B2 (en) |
BR (1) | BR9007016A (en) |
CA (1) | CA2007499C (en) |
FI (1) | FI105453B (en) |
HU (1) | HUT62487A (en) |
IL (1) | IL92996A (en) |
WO (1) | WO1990007952A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2694886A1 (en) * | 1992-08-06 | 1994-02-25 | Zaki George | Extracorporeal blood sterilisation - with combination of UV irradiation and sterilising gas, used for treating blood from patients with bacterial, parasitic, or viral infection. |
FR2698270A1 (en) * | 1992-11-20 | 1994-05-27 | Goupil Jean Jacques | Use of 5-methoxypsoralen in the treatment of AIDS. |
EP0727938A1 (en) * | 1993-11-10 | 1996-08-28 | Steritech, Inc | Device and method for photoactivation |
EP0782388A1 (en) * | 1994-09-22 | 1997-07-09 | Baxter International Inc. | Photodynamic inactivation of viral and bacterial blood contaminants with halogenated coumarin and furocoumarin sensitizers |
WO2000059551A1 (en) * | 1999-04-01 | 2000-10-12 | Gerhard Saalmann | Photodynamic inactivation of viruses in biological fluids |
US6433343B1 (en) | 1992-03-02 | 2002-08-13 | Cerus Corporation | Device and method for photoactivation |
EP1465699A1 (en) * | 2001-12-12 | 2004-10-13 | Leon J. Lewandowski | Photophoretic auto immune stimulation |
WO2008036285A1 (en) * | 2006-09-18 | 2008-03-27 | Energex Systems, Inc. | Method of treating viral infections with ultraviolet light |
GB2509940A (en) * | 2013-01-18 | 2014-07-23 | John Ogino | Vaccine production via irradiation of pathogenic cultures |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
AU2004224425B2 (en) * | 2003-02-06 | 2010-06-24 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321919A (en) * | 1979-12-11 | 1982-03-30 | Leukocyte Research, Inc. | Method and system for externally treating human blood |
US4464166A (en) * | 1981-06-12 | 1984-08-07 | Frederic A. Bourke, Jr. | Method for externally treating the blood |
US4568542A (en) * | 1981-06-09 | 1986-02-04 | Lee Biomolecular Research Laboratories, Inc. | Vaccine compositions |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124363B1 (en) * | 1983-05-02 | 1990-12-19 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
DK507185A (en) * | 1984-11-05 | 1986-05-06 | Du Pont | METHOD OF INACTIVATING HUMAN TUMOR LEUKAEMI VIRUS III |
-
1990
- 1990-01-08 IL IL9299690A patent/IL92996A/en not_active IP Right Cessation
- 1990-01-10 WO PCT/US1990/000275 patent/WO1990007952A1/en not_active Application Discontinuation
- 1990-01-10 HU HU912326A patent/HUT62487A/en unknown
- 1990-01-10 CA CA002007499A patent/CA2007499C/en not_active Expired - Fee Related
- 1990-01-10 BR BR909007016A patent/BR9007016A/en unknown
- 1990-01-10 EP EP19900902445 patent/EP0453497A4/en not_active Withdrawn
- 1990-01-10 JP JP2502474A patent/JPH04502621A/en active Pending
- 1990-01-10 AU AU49545/90A patent/AU638693B2/en not_active Ceased
-
1991
- 1991-07-09 FI FI913318A patent/FI105453B/en active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321919A (en) * | 1979-12-11 | 1982-03-30 | Leukocyte Research, Inc. | Method and system for externally treating human blood |
US4568542A (en) * | 1981-06-09 | 1986-02-04 | Lee Biomolecular Research Laboratories, Inc. | Vaccine compositions |
US4464166A (en) * | 1981-06-12 | 1984-08-07 | Frederic A. Bourke, Jr. | Method for externally treating the blood |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6433343B1 (en) | 1992-03-02 | 2002-08-13 | Cerus Corporation | Device and method for photoactivation |
US6949753B2 (en) | 1992-03-02 | 2005-09-27 | Cerus Corporation | Device and method for photoactivation |
US6586749B2 (en) | 1992-03-02 | 2003-07-01 | Cerus Corporation | Device and method for photoactivation |
FR2694886A1 (en) * | 1992-08-06 | 1994-02-25 | Zaki George | Extracorporeal blood sterilisation - with combination of UV irradiation and sterilising gas, used for treating blood from patients with bacterial, parasitic, or viral infection. |
FR2698270A1 (en) * | 1992-11-20 | 1994-05-27 | Goupil Jean Jacques | Use of 5-methoxypsoralen in the treatment of AIDS. |
EP0604248A1 (en) * | 1992-11-20 | 1994-06-29 | Jean-Jacques Goupil | Use of 5-methoxypsoralen for the treatment of AIDS |
EP0727938A1 (en) * | 1993-11-10 | 1996-08-28 | Steritech, Inc | Device and method for photoactivation |
EP0727938A4 (en) * | 1993-11-10 | 2000-05-10 | Cerus Corp | Device and method for photoactivation |
EP0782388A4 (en) * | 1994-09-22 | 2000-03-08 | Baxter Int | Photodynamic inactivation of viral and bacterial blood contaminants with halogenated coumarin and furocoumarin sensitizers |
EP0782388A1 (en) * | 1994-09-22 | 1997-07-09 | Baxter International Inc. | Photodynamic inactivation of viral and bacterial blood contaminants with halogenated coumarin and furocoumarin sensitizers |
WO2000059551A1 (en) * | 1999-04-01 | 2000-10-12 | Gerhard Saalmann | Photodynamic inactivation of viruses in biological fluids |
EP1465699A1 (en) * | 2001-12-12 | 2004-10-13 | Leon J. Lewandowski | Photophoretic auto immune stimulation |
EP1465699A4 (en) * | 2001-12-12 | 2006-05-24 | Leon J Lewandowski | Photophoretic auto immune stimulation |
WO2008036285A1 (en) * | 2006-09-18 | 2008-03-27 | Energex Systems, Inc. | Method of treating viral infections with ultraviolet light |
GB2509940A (en) * | 2013-01-18 | 2014-07-23 | John Ogino | Vaccine production via irradiation of pathogenic cultures |
Also Published As
Publication number | Publication date |
---|---|
CA2007499C (en) | 2001-03-27 |
AU638693B2 (en) | 1993-07-08 |
IL92996A (en) | 1996-06-18 |
BR9007016A (en) | 1991-11-12 |
JPH04502621A (en) | 1992-05-14 |
FI105453B (en) | 2000-08-31 |
CA2007499A1 (en) | 1990-07-10 |
AU4954590A (en) | 1990-08-13 |
HUT62487A (en) | 1993-05-28 |
FI913318A0 (en) | 1991-07-09 |
EP0453497A1 (en) | 1991-10-30 |
EP0453497A4 (en) | 1992-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4960408A (en) | Treatment methods and vaccines for stimulating an immunological response against retroviruses | |
AU710242B2 (en) | Photopheresis treatment of leukocytes | |
US4838852A (en) | Active specific immune suppression | |
WO1997036581A9 (en) | Photopheresis treatment of leukocytes | |
AU638693B2 (en) | Treatment methods and vaccines | |
DE69734450T2 (en) | PHOTOPHERESIS TREATMENT OF HCV INFECTIONS | |
North et al. | Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative | |
EP0101200A2 (en) | Transfer factor for use in treating viral infections | |
CA2529965C (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
EP0690725A1 (en) | Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells | |
US20200237896A1 (en) | Photochemical Preparation Method for Autologous Plasma Inactivated Vaccine for Treating Aids | |
WO1991012804A1 (en) | New use | |
JPH02501534A (en) | A method for selectively modulating the expression and function of cell surface determinants and the production of novel human cells thereby | |
US20030035813A1 (en) | Immunological treatment methods and agents | |
WO1989009229A1 (en) | Treatment of hiv viremic patients with thymopentin | |
US5219882A (en) | Treatment methods for lymes disease and associated debilitating conditions | |
Gonzalez et al. | Cytolytic response to HIV in patients with HIV disease treated with extracorporeal photochemotherapy: preliminary study | |
RU2099051C1 (en) | Method for treating secondary immunodeficiency | |
Knobler | Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma and other T-lymphocyte mediated diseases | |
WO1997037654A1 (en) | Use of photopheresis in the treatment of chronic infection by hepatitis c virus | |
MXPA98008019A (en) | Treatment for photoferesis of chronic infections for hepatiti viruses | |
Sklavounou-Tsouroutsoglou et al. | Hepatitis B vaccination in children with thalassemia in northern Greece | |
AU2008201523A1 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
Pauza | Disease Progression in AIDS | |
KR20020063153A (en) | A method of AIDS treatment with other person's immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR DK ES FI HU JP NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990902445 Country of ref document: EP Ref document number: 913318 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990902445 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 913318 Country of ref document: FI |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990902445 Country of ref document: EP |